Laser treatment adjunctive to non-surgical periodontal therapy

Efficacy of laser activated 3% hydrogen peroxide and 2% povidone iodine as an adjunct to non-surgical periodontal therapy in stage II periodontitis patients - a randomized clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061873

Enrollment

Registered

2024-01-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: 2% povidone iodine: photoactivation of 2% povidone iodine with 940 nm diode laser with 7 mm length and 300 um diameter uninitiated fiber tip, 1.1 W, continuous wave, exposure time for 3

2% povidone iodine solution will be inserted to the bottom of the periodontal pocket using a disposable plastic needle Intervention2: 3% hydrogen peroxide: photoactivation of 3% hydrogen peroxide with

3% hydrogen peroxide solution will be inserted to the bottom of the periodontal pocket using a disposable plastic needle Intervention3: diode laser: decontamination with diode 940 nm laser with 7 mm

Eligibility

Inclusion criteria

Inclusion criteria: 1. systemically healthy male or female between 18-60 years age 2. at least 20 natural teeth present in the oral cavity distributed in 4 quadrants 3. each quadrant containing at least two teeth with periodontal pocket depth (PPD) of less than or equal to 5 mm and clinical attachment loss (CAL) of 2 mm or greater 4. bleeding on probing (BOP) in all 4 quadrants

Exclusion criteria

Exclusion criteria: 1. patients who are during active periodontal treatment or have had undergone periodontal treatment within 12 months 2. patients who have had antibiotic therapy (systemic or local) over the past 6 months 3. smokers 4. systemic conditions that may affect the therapeutic outcome (diabetes type 1 and 2, immune deficiency, hepatitis B virus, hepatitis C virus, cancer, hematological disorders, epilepsy, etc.) 5. pregnancy, breastfeeding 6. incapacity or refusal to follow the study protocol 7. severe comorbid conditions that may affect life expectancy within 1 year (e.g., metastatic cancer) 8. allergy to iodine

Design outcomes

Primary

Measure	Time frame
Periodontal probing depth (PD) Bleeding on probing (BOP) Clinical attachment level (CAL)Timepoint: The markers will be evaluated at baseline (before treatment) and 3 months after treatment.	—

Secondary

Measure	Time frame
Periodontal probing depth (PD) Bleeding on probing (BOP) Clinical attachment level (CAL)Timepoint: The markers will be evaluated at 1 month after intervention	—

Countries

India

Contacts

Public ContactAvaneendra Talwar

AB Shetty Memorial Institute of Dental Sciences

av_talwar@yahoo.co.in9448832799

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026